| Document |
Document Title |
|
WO/2024/074668A1 |
The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of an USH2A related disease or condition.
|
|
WO/2024/076990A1 |
Described herein are multi-specific antigen binding proteins that bind human fibrin or fibrinogen yC domain and vascular endothelial growth factor, and methods of use thereof. In certain aspects, described herein are pharmaceutical compo...
|
|
WO/2024/077270A1 |
Described herein are immunoresponsive cells engineered to express cytokines and chimeric receptors. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/076688A2 |
Certain embodiments of the invention provide a synthetic genomic safe harbor in the genome of a cell. Certain embodiments provide a method of creating a synthetic genomic safe harbor in a genome. Certain embodiments of the invention prov...
|
|
WO/2024/074110A1 |
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or...
|
|
WO/2024/077130A1 |
The present disclosure relates to compositions and methods for treating bladder cancer. In some embodiments the compositions and methods involve using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (I...
|
|
WO/2024/077109A1 |
The present disclosure relates in some aspects to compositions of UNCI 3A antisense oligonucleotides (ASOs) and methods of using ASOs to alter UNC13A cryptic exon splicing and increase UNC13A protein expression. Such ASOs may be used to ...
|
|
WO/2024/075368A1 |
The present invention includes: a generation step for generating ultrafine bubbles in a liquid so as to generate an ultrafine bubble-containing liquid; and an expression step for applying, to a plant, the ultrafine bubble-containing liqu...
|
|
WO/2024/075756A1 |
Provided is a method for producing a library containing gene-modified cells. This library is useful in the functional evaluation of a specific region of a genome and the introduction, etc., of various types of mutations (such as SNPs) to...
|
|
WO/2024/074705A1 |
The present invention relates to a method of enhancing gene therapy by using an enzyme effective to degrade or digest and/or inhibit or reduce effector function of serum antibodies in the subject. More particularly, the subject is one th...
|
|
WO/2024/076897A2 |
The present disclosure provides methods and compositions for producing, detecting, and selecting soybean plants and seeds comprising at least one high protein CCT (CONSTANS, CO-like and TOC1) domain containing variant allele and introgre...
|
|
WO/2024/077156A2 |
The present disclosure provides for efficient ex vivo processes for generating NK cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or m...
|
|
WO/2024/077238A2 |
Compositions comprising a nucleic acid molecule that encodes TB proteins are disclosed. Methods of inducing an immune response against TB in an individual are disclosed. Method of treating an individual who has been diagnosed with TB are...
|
|
WO/2024/077228A2 |
The disclosure provides, inter alia, compounds comprising a phosphorothioated CpG oligodeoxynucleotide linked to a DNA oligonucleotide that is hybridized to another DNA oligonucleotide that contain a constrained nucleotide, pharmaceutica...
|
|
WO/2024/075803A1 |
The present invention addresses the problem of providing: a method for testing a cranial nerve disease including schizophrenia, or a method for testing the sensitivity to a cranial nerve disease; and a reagent and a kit for use in the te...
|
|
WO/2024/075674A1 |
The purpose of the present technology is to provide: a protein that has a protocatechuic acid 5-position oxidizing activity and can efficiently generate gallic acid from protocatechuic acid; and a microbial strain that expresses said pro...
|
|
WO/2024/075809A1 |
The purpose of the present invention is to provide an antimicrobial agent having reduced allergy properties and containing recombinant psLAAO, and a method for producing this antimicrobial agent. This purpose is solved by an antimicrobia...
|
|
WO/2024/077114A1 |
The invention provides systems and methods for making sequencing libraries that are useful for quantitatively analyzing nucleic acids in a sample. Sample nucleic acids are randomly cleaved at, and PCR. handled are attached to, a random c...
|
|
WO/2024/074464A2 |
Disclosed is a method for treating a renal condition by loco-regional perfusion of one or both of a patient's kidneys. A closed circuit may be formed with a perfusion catheter positioned in the renal artery of the kidney, a recovery cath...
|
|
WO/2024/077257A2 |
Systems and methods for electroporating a biological cell are disclosed. The system includes a microfluidic channel adapted to receive a flow of a plurality of biological cells in a buffer solution. The microfluidic channel comprises a d...
|
|
WO/2024/073842A1 |
The present disclosure generally relates to binding agents that are capable of targeting tumor cells and immune cells. The binding agents of the present disclosure are multispecific and comprise antigen binding domains that are capable o...
|
|
WO/2024/074104A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/076781A1 |
The present disclosure relates to polynucleotides and methods of inhibiting the activities of development- associated pathways, including the Wnt, Hedgehog, and Notch pathways, and the invasive capacity of malignant cells to treat primar...
|
|
WO/2024/075050A1 |
The present application relates to a fusion protein including a follicle stimulating hormone and an antigen-binding fragment to serum albumin and a use thereof. Accordingly, a recombinant fusion protein, which includes an antigen-binding...
|
|
WO/2024/077255A1 |
Transgenic bioincubators are provided having an FAH transgene or endogenous FAH modified with an inducible promoter. The inducible promoter allows for control of the expression of FAH in the presence or absence of an inducer, for purpose...
|
|
WO/2024/077283A2 |
Mitochondrial DNA (mtDNA) in humans is a 16,569 base pair double-stranded circular DNA that encodes 13 vital proteins of the electron transport chain. Embodiments of the invention include allotopic expression of mtDNA genes to compensate...
|
|
WO/2024/077148A1 |
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of PLG, and methods of treating subjects that would benefit from reduction i...
|
|
WO/2024/074143A1 |
Provided is an expression construct, vectors, viral particles, or compositions. The expression construct comprises a transcription regulatory element operably linked to a polynucleotide sequence of interest, wherein the expression constr...
|
|
WO/2024/074825A1 |
The invention concerns a modified adenoviral vector of serotype Ad5 comprising a suicide transgene; a pharmaceutical composition comprising same; a combination therapeutic comprising same, the use of said adenoviral vector or pharmaceuti...
|
|
WO/2024/077262A2 |
Disclosed are compositions and methods for reducing expression of ELAVL2. It has been determined that GGGGCC (G4C2) repeat expansion in the first intron of C9ORF72 is the most commonly known genetic cause of amyotrophic lateral sclerosis...
|
|
WO/2024/076507A1 |
Methods for improving parthenogenesis efficiency by DWT1 and BABY BOOM transcription factors in plants are provided. A rice embryo trigger transcription factor BABY BOOM1 can initiate embryogenesis when expressed in the unfertilized egg ...
|
|
WO/2024/077071A2 |
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, di...
|
|
WO/2024/076530A1 |
This document provides methods and materials for treating a mammal (e.g., a human) having a disease or disorder condition associated with an elevated level of a plurality of senescence-associated secretory phenotype (SASP) polypeptides (...
|
|
WO/2024/076473A1 |
The present disclosure relates to compositions of matter and assay methods used to screen for molecular dimerization events using a two-ribonucleoprotein complex signal boost assay. The compositions and methods provide a readout upon det...
|
|
WO/2024/076525A1 |
The present invention is directed to an agricultural mixture comprising 1-amino-1-cyclopropanecarboxylic acid, a hydrate thereof, a polymorph thereof or a salt thereof and methyl jasmonate. The present invention is further directed to a ...
|
|
WO/2024/074727A1 |
The invention relates to an immune cell engineered to express a chimeric antigen receptor (CAR) which specifically binds Fibroblast Activation Protein (FAP) for use in the treatment of skeletal muscle fibrosis in muscular dystrophies.
|
|
WO/2024/067780A1 |
Provided is a codon optimization method for reducing the immunogenicity of exogenous nucleic acids. The method comprises the following steps: a) obtaining an initial nucleic acid sequence population set, wherein the initial nucleic acid ...
|
|
WO/2024/073669A1 |
Provided herein are methods of treating neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) in a subject in need thereof comprising administering an anti-hVEGF treatment and a steroid treatment; wherein the ...
|
|
WO/2024/065649A1 |
Provided is a method for efficiently loading DNA into an exosome, wherein the exosome is derived from mammalian cells or milk. A highly compressed DNA-polycationic compression agent complex is formed by combining a polycationic compressi...
|
|
WO/2024/066822A1 |
The present invention provides a method for producing γ-butyrolactone or 1,4-butanediol by fermentation. By means of a synthetic biology technique, Corynebacterium glutamicum is taken as a chassis, and an exogenous glutamate decarboxyla...
|
|
WO/2024/071923A1 |
According to an aspect of the technology disclosed in the present application, the present invention relates to a cell line in which exosomes loaded with FAF1 protein are stably expressed, and relates to: a cell line, which can produce, ...
|
|
WO/2024/067888A1 |
Provided is a varicella zoster vaccine. Specifically, the vaccine comprises an immune composition, and the immune composition comprises an antigen component and a granulin component. The granulin component comprises a nanogranulin protei...
|
|
WO/2024/071960A1 |
The present invention relates to: a peptide tag based on a dispersed His-tag and charged and hydrophobic amino acids forming a self-assembly; a fusion protein in which the tag and a target protein are fused; and a target protein purifica...
|
|
WO/2024/068760A1 |
This invention relates to methods of making immunoresponsive cells, immunoresponsive cells thereof, pharmaceutical compositions, kits, uses thereof and methods of treatment. In particular, there is provided a method of making an immunore...
|
|
WO/2024/071527A1 |
The purpose of the present invention is to provide a tag for increasing the expression of a membrane protein and use thereof. Specifically, the tag according to the present invention significantly increases the expression of various type...
|
|
WO/2024/072006A1 |
The present invention relates to a method for generating a total mRNA-based random sgRNA library through an enzymatic reaction. The method according to the present invention may generate an sgRNA library that may target the entire genome...
|
|
WO/2024/069180A2 |
Provided herein are multivalent protein scaffolds useful as therapeutics, and useful in identifying new therapeutic compounds. The invention also relates to multi-domain polypeptide constructs having multiple binding domains and a struct...
|
|
WO/2024/068990A1 |
The present invention relates to a chimeric helper nucleic acid molecule comprising helper elements from three distinct helper viruses, helper-free virus methods and systems for producing infectious recombinant adeno-associated virus (rA...
|
|
WO/2024/071039A1 |
The present disclosure provides a pharmaceutical composition for treating or preventing T cell-related disorders, the pharmaceutical composition containing induced regulatory T cells having high functionality and a stable immunosuppressi...
|
|
WO/2024/073755A2 |
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids ("BIAs") such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocod...
|
